Icotyde Advances Toward European Approval

Company Johnson & Johnson (Janssen-Cilag International) Event Type Regulatory Milestone (Positive CHMP Opinion) Modality Oral Macrocyclic Peptide (IL-23 Receptor Antagonist) Asset Icotyde (icotrokinra) Target IL-23 Receptor Disease Area Moderate-to-Severe Plaque Psoriasis Summary Europe’s medicines committee recommended Icotyde, or icotrokinra, for adults and adolescents aged 12…